Hypoparathyroidism

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone (PTH). This can lead to low levels of calcium in the blood, often causing cramping and twitching of muscles or tetany (involuntary muscle contraction), and several other symptoms. It is a very rare disease. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The diagnosis is made with blood tests, and other investigations such as genetic testing depending on the results. The primary treatment of hypoparathyroidism is calcium and vitamin D supplementation. Calcium replacement or vitamin D can ameliorate the symptoms but can increase the risk of kidney stones and chronic kidney disease.<ref name=Bilezikian/> Additionally, medications such as recombinant human parathyroid hormone or teriparatide may be given by injection to replace the missing hormone.<ref>Template:Cite journal</ref>

Signs and symptoms

The main symptoms of hypoparathyroidism are the result of the low blood calcium level, which interferes with normal muscle contraction and nerve conduction. As a result, people with hypoparathyroidism can experience paresthesia, an unpleasant tingling sensation around the mouth and in the hands and feet, as well as muscle cramps and severe spasms known as "tetany" that affect the hands and feet.<ref name=Shoback>Template:Cite journal</ref> Many also report a number of subjective symptoms such as fatigue, headaches, bone pain and insomnia.<ref name=Bilezikian>Template:Cite journal</ref> Crampy abdominal pain may occur.<ref name=Potts>Template:Cite book</ref> Physical examination of someone with hypocalcemia may show tetany, but it is also possible to provoke tetany of the facial muscles by tapping on the facial nerve (a phenomenon known as Chvostek's sign) or by using the cuff of a sphygmomanometer to temporarily obstruct the blood flow to the arm (a phenomenon known as Trousseau's sign of latent tetany).<ref name=Potts/>

A number of medical emergencies can arise in people with low calcium levels. These are seizures, severe irregularities in the normal heart beat (specifically prolongation of the QT interval), as well as spasm of the upper part of the airways or the smaller airways known as the bronchi (both potentially causing respiratory failure).<ref name=Bilezikian/><ref name="Gafni 2019">Template:Cite journal</ref>

Related conditions

Condition		Appearance	PTH levels	Calcitriol	Calcium	Phosphates	Imprinting
Hypoparathyroidism		Normal	Low	Low	Low	High	Not applicable
Pseudohypoparathyroidism	Type 1A	Skeletal defects	High	Low	Low	High	Gene defect from mother (GNAS1)
	Type 1B	Normal	High	Low	Low	High	Gene defect from mother (GNAS1 and STX16)
	Type 2	Normal	High	Low	Low	High	?
Pseudopseudohypoparathyroidism		Skeletal defects	Normal	Normal	Normal<ref name="HussainLatif2010">Template:Cite book</ref>	Normal	gene defect from father

Causes

Hypoparathyroidism can have the following causes:<ref name=Bilezikian/>

• Removal of, or trauma to, the parathyroid glands due to anterior neck surgery (including thyroid surgery) (thyroidectomy), parathyroid surgery (parathyroidectomy). This is the most common cause of hypoparathyroidism, with 78% of cases of hypoparathyroidism arising due to a complication of anterior neck surgery.<ref name="Gafni 2019" /> Although surgeons generally make attempts to spare normal parathyroid glands at surgery, inadvertent injury to the glands or their blood supply is still common. When this happens, the parathyroids may cease functioning. This is usually temporary but occasionally long term (permanent). Hypoparathyroidism may occur as a complication in up to 8% of anterior neck surgeries with 75% of those resolving by 6 months, and 25% of those having permanent hypoparathyroidism.<ref name="Gafni 2019" />
• Kenny–Caffey syndrome
• Autoimmune invasion and destruction is the most common non-surgical cause. It can occur as part of autoimmune polyendocrine syndromes.
• Hemochromatosis can lead to iron accumulation and consequent dysfunction of a number of endocrine organs, including the parathyroids.
• Absence or dysfunction of the parathyroid glands is one of the components of chromosome 22q11 microdeletion syndrome (other names: DiGeorge syndrome, Schprintzen syndrome, velocardiofacial syndrome).
• Magnesium deficiency
• A defect in the calcium receptor leads to a rare congenital form of the disease
• Idiopathic (of unknown cause)
• Occasionally due to other hereditary causes (e.g. Barakat syndrome (HDR syndrome) a genetic development disorder resulting in hypoparathyroidism, sensorineural deafness, and kidney disease)

Mechanism

The parathyroid glands are so named because they are usually located behind the thyroid gland in the neck. They arise during fetal development from structures known as the third and fourth pharyngeal pouch. The glands, usually four in number, contain the parathyroid chief cells that sense the level of calcium in the blood through the calcium-sensing receptor and secrete parathyroid hormone. Magnesium is required for PTH secretion. Under normal circumstances, the parathyroid glands secrete PTH to maintain a calcium level within normal limits, as calcium is required for adequate muscle and nerve function (including the autonomic nervous system).

PTH acts on several organs to regulate calcium levels and phosphorus levels. PTH acts on the kidneys to increase calcium reabsorption into the blood, and to inhibit phosphorus reabsorption (which causes phosphorus to be lost in the urine).<ref name="Gafni 2019" /> It increases calcium and phosphorus absorption in the bowel indirectly by stimulating the kidneys to produce vitamin D which then acts on the gut.<ref name="Gafni 2019" /> PTH also causes increase bone resorption which leads to the releases calcium and phosphorus into the blood.<ref name="Gafni 2019" />

Diagnosis

Diagnosis is by measurement of calcium, serum albumin (for correction) and PTH in blood. If necessary, measuring cAMP (cyclic AMP) in the urine after an intravenous dose of PTH can help in the distinction between hypoparathyroidism and other causes.Template:Citation needed

Differential diagnoses are:

• Pseudohypoparathyroidism (normal PTH levels but tissue insensitivity to the hormone, associated with intellectual disability and skeletal deformities) and pseudopseudohypoparathyroidism.<ref>Template:Cite journal</ref>
• Vitamin D deficiency or hereditary insensitivity to this vitamin (X-linked dominant).
• Malabsorption
• Kidney disease
• Medication: steroids, diuretics, some antiepileptics.

Other tests include ECG for abnormal heart rhythms, and measurement of blood magnesium levels.Template:Citation needed

Treatment

Severe hypocalcaemia, a potentially life-threatening condition, is treated as soon as possible with intravenous calcium (e.g. as calcium gluconate). Calcium gluconate can be given via a peripheral IV, however other calcium formulations require infusion via a central venous catheter as the calcium can irritate peripheral veins and cause phlebitis.<ref name="Gafni 2019" /> Precautions are taken to prevent seizures or larynx spasms. The heart is monitored for abnormal rhythms during IV treatment as calcium may affect cardiac conduction.<ref name="Gafni 2019" /> When the life-threatening attack has been controlled, the person is then transitioned to long term therapy with oral or subcutaneous injection medications.<ref name="Gafni 2019" />

Long-term treatment of hypoparathyroidism is with vitamin D analogs (such as calcitriol or alfacalcidol), vitamin D supplementation and calcium supplementation.<ref name="Gafni 2019" /> Potential risks of treatment for hypoparathyroidism include hypercalcemia and hypercalciuria (elevated calcium in the urine) which may lead to kidney calcification (nephrocalcinosis) and chronic kidney disease.<ref name="Gafni 2019" /><ref>Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism: Results of a randomized crossover trial" JAMA 1996;276:631-636</ref> Calcium levels in the blood and urine (along with other electrolytes) must be monitored during long-term treatment of hypoparathyroidism and blood calcium levels are intentionally kept at the lower limits of normal, or mildly low, specifically to avoid hypercalciuria, kidney calcification and kidney damage.<ref name="Gafni 2019" />

Recombinant human parathyroid hormone and teriparatide (which consists of the first N-terminal 34 amino acids of parathyroid hormone, the bioactive portion of the hormone)(PTH 1-34) may be used as a second line therapy in those that have not responded to conventional therapy.<ref name="Gafni 2019" /> Both medication may be given via subcutaneous injections, but the use of pump delivery of synthetic PTH 1-34 provides the closest approach to physiologic PTH replacement therapy.<ref>Winer KK, Zhang B, Shrader J, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. Nov.2011.</ref> Recombinant human parathyroid hormone and teriparatide are also associated with a risk of hypercalcemia, hypercalciuria with associated kidney calcification and kidney damage.<ref name="Gafni 2019" /> If these medications are discontinued, they should be tapered and calcium levels should be closely monitored as the transient PTH depletion after stopping the medications can lead to bone leaching of calcium as a compensatory mechanism to increase calcium levels.<ref name="Gafni 2019" />

A 2019 systematic review has highlighted that because of the research gap in recent rigorous studies, there is a lack of high-quality evidence for the use of vitamin D, calcium, or recombinant parathyroid hormone in the management of both temporary and long-term hypoparathyroidism following thyroidectomy.<ref>Template:Cite journal</ref>

Kidney ultrasound may be considered periodically to assess for any nephrocalcinosis for those on long term therapy for hypoparathyroidism.<ref name="Gafni 2019" />

See also

• Hyperparathyroidism

External links

Template:Parathyroid disease {{#invoke:Navbox|navbox}} Template:Authority control